Status:
ACTIVE_NOT_RECRUITING
Prognostic's Factors of Head and Neck Paragangliomas Evolution
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Paraganglioma
Eligibility:
All Genders
18+ years
Brief Summary
Cervical paragangliomas (HNPG) are rare tumors (0.6% of head and neck tumors) arising from chromaffin tissue, of cervical paraganglia (PGL). The most common locations are carotid body (60% of cases), ...
Eligibility Criteria
Inclusion
- Man or woman aged 18 or over
- Patient with a confirmed diagnosis of one or multiple cervical paragangliomas regardless of genetic predisposition without specific therapy
- Patient informed of the study details and who didn't opposed to participate in this research
Exclusion
- Patient already treated without initial clinical and radiologic assessment standardized
- Patient already treated with surgery, radiotherapy or systemic therapy for another paraganglioma
- Patient with evolutive disease and life expectancy less than 2 years
- Patient placed under legal protection
- Patient participating in another interventional clinical study that may interfere with the results of this study
Key Trial Info
Start Date :
July 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05233878
Start Date
July 19 2022
End Date
June 1 2027
Last Update
June 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fédération d'endocrinologie Hôpital Cardiologique/Groupement Hospitalier Est
Bron, France, 69500